Welcome to NGC. Skip directly to: Search Box, Navigation, Content.


Complete Summary

GUIDELINE TITLE

Guidelines on the management of massive blood loss.

BIBLIOGRAPHIC SOURCE(S)

GUIDELINE STATUS

This is the current release of the guideline.

COMPLETE SUMMARY CONTENT

 
SCOPE
 METHODOLOGY - including Rating Scheme and Cost Analysis
 RECOMMENDATIONS
 EVIDENCE SUPPORTING THE RECOMMENDATIONS
 BENEFITS/HARMS OF IMPLEMENTING THE GUIDELINE RECOMMENDATIONS
 QUALIFYING STATEMENTS
 IMPLEMENTATION OF THE GUIDELINE
 INSTITUTE OF MEDICINE (IOM) NATIONAL HEALTHCARE QUALITY REPORT CATEGORIES
 IDENTIFYING INFORMATION AND AVAILABILITY
 DISCLAIMER

SCOPE

DISEASE/CONDITION(S)

Massive blood loss

GUIDELINE CATEGORY

Evaluation
Management
Treatment

CLINICAL SPECIALTY

Anesthesiology
Cardiology
Critical Care
Emergency Medicine
Hematology
Obstetrics and Gynecology
Pediatrics
Surgery

INTENDED USERS

Clinical Laboratory Personnel
Hospitals
Physicians

GUIDELINE OBJECTIVE(S)

To provide healthcare professionals with clear guidance on the management of massive blood loss

TARGET POPULATION

Patients in the United Kingdom with massive blood loss

Note: Women with major obstetric haemorrhage are not included.

INTERVENTIONS AND PRACTICES CONSIDERED

Evaluation

  1. Blood levels of hemoglobin, platelets, and erythrocytes
  2. Hematocrit levels
  3. Blood levels of calcium and potassium
  4. Coagulopathy: prothrombin time (PT), activated partial thromboplastin time (APTT), D dimer measurement

Management

  1. Interdisciplinary transfusion committee
  2. Interdepartment communications
  3. Referral of care
  4. Blood typing
  5. Blood component processing
  6. Risk assessment

Treatment

  1. Volume resuscitation (crystalloid versus colloid; albumin versus saline; prewarming)
  2. Erythrocyte transfusion
  3. Platelet transfusion
  4. Fresh frozen plasma (FFP) and cryoprecipitate
  5. Antifibrinolytics (tranexamic acid, aprotinin)
  6. Recombinant factor VIIa

MAJOR OUTCOMES CONSIDERED

  • Incidence of transfusion side effects
  • Mortality

METHODOLOGY

METHODS USED TO COLLECT/SELECT EVIDENCE

Searches of Electronic Databases

DESCRIPTION OF METHODS USED TO COLLECT/SELECT THE EVIDENCE

Preparation of the guidelines included a review of key literature, including Cochrane Database and MEDLINE and consultation with representatives of relevant specialties.

NUMBER OF SOURCE DOCUMENTS

Not stated

METHODS USED TO ASSESS THE QUALITY AND STRENGTH OF THE EVIDENCE

Weighting According to a Rating Scheme (Scheme Given)

RATING SCHEME FOR THE STRENGTH OF THE EVIDENCE

Classification of Evidence Levels

Ia Evidence obtained from meta-analysis of randomised controlled trials.

Ib Evidence obtained from at least one randomised controlled trial.

IIa Evidence obtained from at least one well-designed controlled study without randomisation.

IIb Evidence obtained from at least one other type of well-designed quasi-experimental study (refers to a situation in which implementation of an intervention is without the control of the investigators, but an opportunity exists to evaluate its effect).

III Evidence obtained from well-designed non-experimental descriptive studies, such as comparative studies, correlation studies and case studies.

IV Evidence obtained from expert committee reports or opinions and/or clinical experiences of respected authorities.

METHODS USED TO ANALYZE THE EVIDENCE

Systematic Review

DESCRIPTION OF THE METHODS USED TO ANALYZE THE EVIDENCE

Not stated

METHODS USED TO FORMULATE THE RECOMMENDATIONS

Expert Consensus

DESCRIPTION OF METHODS USED TO FORMULATE THE RECOMMENDATIONS

Recommendations are based on appraisal of the relevant literature and expert consensus.

The guideline group was selected to be representative of United Kingdom (UK)-based medical experts and included the authors of previous recommendations.

The writing group produced the draft guideline, which was subsequently revised by consensus by members of the Transfusion Task Force of the British Committee for Standards in Haematology.

RATING SCHEME FOR THE STRENGTH OF THE RECOMMENDATIONS

Classification of Grades of Recommendations

Grade A Requires at least one randomised controlled trial as part of a body of literature of overall good quality and consistency addressing specific recommendation. (Evidence levels Ia, Ib).

Grade B Requires the availability of well conducted clinical studies but no randomised clinical trials on the topic of recommendation. (Evidence levels IIa, IIb, III).

Grade C Requires evidence obtained from expert committee reports or opinions and/or clinical experiences of respected authorities. Indicates an absence of directly applicable clinical studies of good quality. (Evidence level IV).

COST ANALYSIS

A formal cost analysis was not performed and published cost analyses were not reviewed.

METHOD OF GUIDELINE VALIDATION

External Peer Review
Internal Peer Review

DESCRIPTION OF METHOD OF GUIDELINE VALIDATION

The guideline was reviewed by a sounding board of approximately 100 United Kingdom haematologists, the British Committee for Standards in Haematology (BCSH) and the British Society for Haematology Committee and comments incorporated where appropriate.

RECOMMENDATIONS

MAJOR RECOMMENDATIONS

A summary of key recommendations is presented as a template that can be modified to suit local circumstances, and then displayed in clinical areas. The left-hand column outlines the key steps or goals, the centre column adds procedural detail and the right-hand column provides additional advice and information (Table below).

Table I. Summary of Key Recommendations


Goal Procedure Comments
Restore circulating volume Insert wide bore peripheral or central cannulae

Give pre-warmed crystalloid or colloid as needed

Avoid hypotension or urine output <0.5 ml/kg/h
14 gauge

Monitor central venous pressure

Keep patient warm

Concealed blood loss is often underestimated
Contact key personnel Clinician in charge

Consultant anaesthetist

Blood transfusion Biomedical Scientist

Haematologist
A named senior person must take responsibility for communication and documentation.

Arrange Intensive Care Unit bed
Arrest bleeding Early surgical or obstetric intervention

Interventional radiology
 
Request laboratory investigations FBC, PT, APTT, Thrombin time, Fibrinogen (Clauss method); blood bank sample, biochemical profile, blood gases and pulse oximetry

Ensure correct sample identification

Repeat tests after blood component infusion
Results may be affected by colloid infusion

Ensure correct patient identification

May need to give components before results available
Maintain Hb >8 g/dl Assess degree of urgency  
Employ blood salvage to minimise allogeneic blood use Collection of spilt blood can be set up in <10 min
Give red cells  

Group O Rh D negative

 

In extreme emergency

D positive is acceptable if patient is male or postmenopausal female

Until ABO and Rh D groups known

ABO group specific when blood group known

 

Fully compatible blood

Time permitting

Further serological crossmatch not required after 1 blood volume replacement
Use blood warmer and/or rapid infusion device if flow rate >50 ml/kg/h in adult Transfusion laboratory will complete crossmatch after issue
Maintain platelet count >75 x 109/l Allow for delivery time from blood centre

Anticipate platelet count <50 x 109/l. after 2 x blood volume replacement
Allows margin of safety to ensure platelet count >50 x 109/l

Keep platelet count >100 x 109./l if multiple or CNS trauma or if platelet function abnormal
Maintain PT & APTT <1.5 × mean control Give FFP 12 to 15 ml/kg (1 l or four units for an adult) guided by tests

Anticipate need for FFP after 1 to 1.5 x blood volume replacement

Allow for 30 min thawing time
PT/APTT >1.5 x mean normal value correlates with increased microvascular bleeding

Keep ionised Ca2+ >1.13 mmol/l
Maintain Fibrinogen >1.0 g/l If not corrected by FFP give cryoprecipitate (Two packs of pooled cryoprecipitate for an adult)

Should be available on-site. Allow for 30 min thawing time
Cryoprecipitate rarely needed except in DIC
Avoid DIC Treat underlying cause (shock, hypothermia, acidosis) Although rare, mortality is high

FBC, full blood count; PT, prothrombin time; APTT, activated partial thromboplastin time; FFP, fresh frozen plasma; DIC, disseminated intravascular coagulation

CLINICAL ALGORITHM(S)

None provided

EVIDENCE SUPPORTING THE RECOMMENDATIONS

TYPE OF EVIDENCE SUPPORTING THE RECOMMENDATIONS

Recommendations are based on appraisal of the relevant literature and expert consensus.

BENEFITS/HARMS OF IMPLEMENTING THE GUIDELINE RECOMMENDATIONS

POTENTIAL BENEFITS

  • Reduced requirements for allogeneic blood transfusion
  • Reduced non-haemolytic febrile transfusion reactions, transmission of leucocyte-associated viruses (i.e., cytomegalovirus), and immunosuppressive effects of transfusion and reduced cytokine-mediated organ damage with leucodepletion
  • Early recognition of major blood loss and institution of effective actions may prevent shock and its consequences.
  • Maintenance of tissue perfusion and oxygenation by restoration of blood volume and hemoglobin
  • Arrest of bleeding by treating any traumatic, surgical or obstetric source and judicious use of blood component therapy to correct coagulopathy
  • Improved survival

POTENTIAL HARMS

  • Giving of the wrong blood to the patient, which can result in a fatal haemolytic reaction
  • Fatal hemolytic reaction
  • Transfusion-related acute lung injury and other acute immunologically mediated transfusion reactions (i.e., graft versus host disease)
  • Hypocalcemia, causing reduced myocardial contractility, vasodilation, further bleeding, and shock
  • Hyperkalemia, causing metabolic acidosis and shock
  • Hypothermia
  • Transmission of infection

QUALIFYING STATEMENTS

QUALIFYING STATEMENTS

  • In all cases individual patient circumstances may dictate an alternative approach.
  • While the advice and information in these guidelines is believed to be true and accurate at the time of going to press, neither the authors, the British Society for Haematology nor the publishers accept any legal responsibility for the content of these guidelines.

IMPLEMENTATION OF THE GUIDELINE

DESCRIPTION OF IMPLEMENTATION STRATEGY

Suggested Topics for Audit

  1. Initial resuscitation with crystalloids should be preceded by blood sampling for full blood count, coagulation screen, biochemistry, blood gases and blood grouping.
  2. Documentation (using a designated checklist sheet and identified member of the resuscitation team) should consist of a minimum dataset that must record: type of blood component or replacement fluid, time given, amount (dosage), indication for replacement, effectiveness of the transfusion. Full traceability of blood components given.
  3. Local protocols and algorithms must be available and displayed in high-risk units e.g., Accident and emergency, Intensive care units, Theatre and blood banks.
  4. Regular practices of emergency management of massive transfusion should be held and learning points documented to inform protocol development.
  5. Regular retrospective audit of management of massive transfusions – review by Transfusion Team and Hospital Transfusion Committee against the guidelines with learning points documented to inform protocol review.

IMPLEMENTATION TOOLS

Audit Criteria/Indicators
Quick Reference Guides/Physician Guides

For information about availability, see the "Availability of Companion Documents" and "Patient Resources" fields below.

INSTITUTE OF MEDICINE (IOM) NATIONAL HEALTHCARE QUALITY REPORT CATEGORIES

IOM CARE NEED

Getting Better
Living with Illness

IOM DOMAIN

Effectiveness
Safety

IDENTIFYING INFORMATION AND AVAILABILITY

BIBLIOGRAPHIC SOURCE(S)

ADAPTATION

Not applicable: The guideline was not adapted from another source.

DATE RELEASED

2006 Dec

GUIDELINE DEVELOPER(S)

British Committee for Standards in Haematology - Professional Association

GUIDELINE DEVELOPER COMMENT

Not applicable

SOURCE(S) OF FUNDING

British Committee for Standards in Haematology

GUIDELINE COMMITTEE

Writing Group

COMPOSITION OF GROUP THAT AUTHORED THE GUIDELINE

Writing Group Members: D. Stainsby, National Blood Service; S. MacLennan, National Blood Service; D. Thomas, Morriston Hospital, Swansea; J. Isaac, University Hospitals, Birmingham; P. J. Hamilton, Royal Victoria Infirmary, Newcastle upon Tyne, UK

Task Force Members: Dr Frank Boulton (Chair); Dr Dorothy Stainsby (Secretary); Ms Andrea Blest; Dr Hari Boralessa; Dr Hannah Cohen; Mr Chris Elliott; Dr Brian McClelland; Dr Hafiz Qureshi; Dr Megan Rowley; Dr Gillian Turner; Dr Keith Wilson

FINANCIAL DISCLOSURES/CONFLICTS OF INTEREST

None of the authors has declared a conflict of interest.

GUIDELINE STATUS

This is the current release of the guideline.

GUIDELINE AVAILABILITY

Electronic copies: Available from the British Committee for Standards in Haematology Web site.

Print copies: Available from the British Committee for Standards in Haematology; Email: bcsh@b-s-h.org.uk.

AVAILABILITY OF COMPANION DOCUMENTS

None available

PATIENT RESOURCES

None available

NGC STATUS

This NGC summary was completed by ECRI Institute on May 27, 2008. The information was verified by the guideline developer on June 30, 2008.

COPYRIGHT STATEMENT

DISCLAIMER

NGC DISCLAIMER

The National Guideline Clearinghouse™ (NGC) does not develop, produce, approve, or endorse the guidelines represented on this site.

All guidelines summarized by NGC and hosted on our site are produced under the auspices of medical specialty societies, relevant professional associations, public or private organizations, other government agencies, health care organizations or plans, and similar entities.

Guidelines represented on the NGC Web site are submitted by guideline developers, and are screened solely to determine that they meet the NGC Inclusion Criteria which may be found at http://www.guideline.gov/about/inclusion.aspx .

NGC, AHRQ, and its contractor ECRI Institute make no warranties concerning the content or clinical efficacy or effectiveness of the clinical practice guidelines and related materials represented on this site. Moreover, the views and opinions of developers or authors of guidelines represented on this site do not necessarily state or reflect those of NGC, AHRQ, or its contractor ECRI Institute, and inclusion or hosting of guidelines in NGC may not be used for advertising or commercial endorsement purposes.

Readers with questions regarding guideline content are directed to contact the guideline developer.


 

 

   
DHHS Logo